The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary Fibrosis
Open accessAbstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology with a variable and unpredictable course. Objectives: The aim of this study was to identify and validate plasma proteins that are predictive of outcome in IPF. Methods: Plasma samples were available for 241 patients with IPF (140 derivation and 101 validation). In the derivation cohort, concentrations of 92 proteins were analyzed using a multiplex bead-based immunoassay and concentrations of matrix metalloproteinase (MMP)-7, MMP-1, and surfactant protein D were assessed by ELISA. In the validation cohort concentrations of intercellular adhesion molecule (ICAM)-1, IL-8, and vascular cell adhesion molecule (VCAM)-1 were assessed by bead-based multiplex assay, and S100A12 and MMP-7 by ELISA. Associations of biomarkers with mortality, transplant-free survival, and disease progression were tested in the derivation and validation cohorts using nonparametric methods of survival analysis and the Cox proportional hazards model, and an integrated risk prediction score was derived and tested. Measurements and Main Results: High concentrations of MMP-7, ICAM-1, IL-8, VCAM-1, and S100A12 predicted poor overall survival, poor transplant-free survival, and poor progression-free survival in the derivation cohort. In the independent validation cohort high concentrations of all five were predictive of poor transplant-free survival; MMP-7, ICAM-1, and IL-8 of overall survival; and ICAM-1 of poor progression-free survival. The personal clinical and molecular mortality prediction index derived in the derivation cohort was highly predictive of mortality in the validation cohort. Conclusions: Our results suggest that plasma proteins should be evaluated as a tool for prognosis determination in prioritization of patients for lung transplantation and stratification in drug studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High plasma concentrations of MMP7, vascular cell adhesion molecule (VCAM)-1, S100A12, intercellular adhesion molecule (ICAM)1, and IL-8 predicted poor overall survival, transplant-free survival, and progression-free survival in an IPF derivation cohort of 141 patients, while all five were predictive of poor transplant-free survival; MMP7, ICAM-1, and IL-8 of over”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Richards et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statisctics and computing/Statistics and computing · doi:10.1007/978-0-387-21706-2 · Cited by 25,941
Gentleman R: R: A language for data analysis and graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,747
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870
Krämer, W. (2003) · Computational Statistics & Data Analysis · Cited by 1,858
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,807
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Uno, H., Cai, T., Pencina, M. J., D'Agostino, R. B., & Wei, L. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4154 · Cited by 1,535
Willis, B. C., Liebler, J. M., Luby‐Phelps, K., Nicholson, A. G., Crandall, E. D., du Bois, R. M., & Borok, Z. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62351-6 · Cited by 973
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Cited by
Sorted by citations
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,378
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Donato, R., Cannon, B. R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D. J., & Geczy, C. L. (2012) · Current Molecular Medicine · doi:10.2174/156652413804486214 · Cited by 1,354
The Impact of TGF-β on Lung Fibrosis: From Targeting to Biomarkers
Fernandez, I. E., & Eickelberg, O. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201203-023aw · Cited by 704
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Noth, I., Zhang, Y., Ma, S., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. S., Hysi, P. G., Scuirba, J., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70045-6 · Cited by 622
Self-citationPeljto, A. L., Zhang, Y., Fingerlin, T. E., Ma, S., Garcia, J. G. N., Richards, T. J., Silveira, L. J., Lindell, K. O., Steele, M. P., Loyd, J. E., et al. (2013) · JAMA · doi:10.1001/jama.2013.5827 · Cited by 469
Self-citationWhat's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M. R. J., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 361
Herazo-Maya, J. D., Noth, I., Duncan, S. R., Kim, S., Ma, S.-F., Tseng, G. C., Feingold, E., Juan-Guardela, B. M., Richards, T. J., Lussier, Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005964 · Cited by 325
Self-citationJenkins, R. G., Simpson, J. K., Saini, G., Bentley, J. H., Russell, A.-M., Braybrooke, R., Molyneaux, P. L., McKeever, T. M., Wells, A. U., Flynn, A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00048-x · Cited by 314
Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis
Pardo, A., Cabrera, S., Maldonado, M., & Selman, M. (2016) · Respiratory Research · doi:10.1186/s12931-016-0343-6 · Cited by 307
Antoniou, K. M., Margaritopoulos, G. A., Tomassetti, S., Bonella, F., Costabel, U., & Poletti, V. E. (2014) · European Respiratory Review · doi:10.1183/09059180.00009113 · Cited by 294
The natural history of progressive fibrosing interstitial lung diseases
Kolb, M. R. J., & Vašáková, M. (2019) · Respiratory Research · doi:10.1186/s12931-019-1022-1 · Cited by 281
Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N. C., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 276
The epithelium in idiopathic pulmonary fibrosis: breaking the barrier
Camelo, A., Dunmore, R., Sleeman, M. A., & Clarke, D. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00173 · Cited by 260
Scott, M. K. D., Quinn, K., Li, Q., Carroll, R. J., Warsinske, H., Vallania, F., Chen, S., Carns, M. A., Aren, K., Sun, J., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30508-3 · Cited by 240
Self-citationEvans, C. M., Fingerlin, T. E., Schwarz, M. I., Lynch, D. A., Kurche, J. S., Warg, L. A., Yang, I. V., & Schwartz, D. A. (2016) · Physiological Reviews · doi:10.1152/physrev.00004.2016 · Cited by 243
Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report
Blackwell, T. S., Tager, A. M., Borok, Z., Moore, B. B., Schwartz, D. A., Anstrom, K. J., Bar‐Joseph, Z., Bitterman, P. B., Blackburn, M. R., Bradford, W. S., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1141ws · Cited by 243
Self-citationWare, L. B., Koyama, T., Zhao, Z., Janz, D. R., Wickersham, N. E., Bernard, G. R., May, A. K., Calfee, C. S., & Matthay, M. A. (2013) · Critical Care · doi:10.1186/cc13080 · Cited by 227
Role of interleukins in the pathogenesis of pulmonary fibrosis
She, Y. X., Yu, Q. Y., & Tang, X. X. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00437-9 · Cited by 231
Detection of Rheumatoid Arthritis–Interstitial Lung Disease Is Enhanced by Serum Biomarkers
Doyle, T. J., Patel, A. S., Hatabu, H., Nishino, M., Wu, G., Osorio, J. C., Golzarri, M. F., Traslosheros, A., Chu, S. G., Frits, M. L., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-1950oc · Cited by 219
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
Ohshimo, S., Ishikawa, N., Horimasu, Y., Hattori, N., Hirohashi, N., Tanigawa, K., Kohno, N., Bonella, F., Guzman, J., & Costabel, U. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.04.009 · Cited by 202
Predictors of mortality in chronic pulmonary aspergillosis
Lowes, D., Al-Shair, K., Newton, P. J., Morris, J., Harris, C., Rautemaa-Richardson, R., & Denning, D. W. (2017) · European Respiratory Journal · doi:10.1183/13993003.01062-2016 · Cited by 194
Natural history of idiopathic pulmonary fibrosis
Kim, H. J., Perlman, D., & Tomic, R. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.002 · Cited by 191
Kahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190
Self-citationMonocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Kreuter, M., Lee, J. S., Tzouvelekis, A., Oldham, J. M., Molyneaux, P. L., Weycker, D. A., Atwood, M., Kirchgaessler, K.-U., & Maher, T. M. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0669oc · Cited by 191
The Toll-like Receptor 3 L412F Polymorphism and Disease Progression in Idiopathic Pulmonary Fibrosis
O’Dwyer, D. N., Armstrong, M. E., Trujillo, G., Cooke, G., Keane, M. P., Fallon, P. G., Simpson, A. J., Millar, A., McGrath, E. E., Whyte, M. K. B., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0760oc · Cited by 188
Kropski, J. A., Pritchett, J. M., Zoz, D. F., Crossno, P. F., Markin, C. R., Garnett, E. T., Degryse, A. L., Mitchell, D. B., Polosukhin, V. V., Rickman, O. B., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1162oc · Cited by 184
Diagnosis and management of interstitial lung disease
Meyer, K. C. (2014) · Translational Respiratory Medicine · doi:10.1186/2213-0802-2-4 · Cited by 179
Herazo-Maya, J. D., Sun, J., Molyneaux, P. L., Li, Q., Villalba, J. A., Tzouvelekis, A., Lynn, H., Juan-Guardela, B. M., Risquez, C., Osorio, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30349-1 · Cited by 175
Self-citationTranscriptional regulatory model of fibrosis progression in the human lung
McDonough, J. E., Ahangari, F., Li, Q., Jain, S., Verleden, S. E., Herazo‐Maya, J. D., Vukmirovic, M., DeIuliis, G., Tzouvelekis, A., Tanabe, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131597 · Cited by 174
Self-citationRyu, C., Sun, H., Gulati, M., Herazo-Maya, J. D., Chen, Y., Osafo-Addo, A., Brandsdorfer, C., Winkler, J., Blaul, C., Faunce, J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201612-2480oc · Cited by 171
Self-citationMolecular biomarkers in idiopathic pulmonary fibrosis
Ley, B., Brown, K. K., & Collard, H. R. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00014.2014 · Cited by 176
High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study
Podolanczuk, A. J., Oelsner, E. C., Barr, R. G., Hoffman, E. A., Armstrong, H. F., Austin, J. H. M., Basner, R. C., Bartels, M. N., Christie, J. D., Enright, P., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00129-2016 · Cited by 167
Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients
Xue, J., Kass, D. J., Bon, J. M., Vuga, L. J., Tan, J., Csizmadia, E., Otterbein, L. E., Soejima, M., Levesque, M. C., Gibson, K. F., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203476 · Cited by 165
Self-citationSubclinical Interstitial Lung Disease: Why You Should Care
Doyle, T. J., Hunninghake, G. M., & Rosas, I. O. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1420pp · Cited by 158
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression
Chien, J. W., Richards, T. J., Gibson, K. F., Zhang, Y., Lindell, K. O., Shao, L., Lyman, S. K., Adamkewicz, J. I., Smith, V., Kaminski, N., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00141013 · Cited by 160
Self-citationBlood Biomarkers in Idiopathic Pulmonary Fibrosis
Guiot, J., Moermans, C., Henket, M., Corhay, J.-L., & Louis, R. (2017) · Lung · doi:10.1007/s00408-017-9993-5 · Cited by 147
Precision medicine advances in idiopathic pulmonary fibrosis
Karampitsakos, Τ., Juan-Guardela, B. M., Τzouvelekis, Α., & Herazo‐Maya, J. D. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104766 · Cited by 148
Biomarkers of Rheumatoid Arthritis–Associated Interstitial Lung Disease
Chen, J., Doyle, T. J., Liu, Y., Aggarwal, R., Wang, X., Shi, Y., Ge, S., Huang, H., Lin, Q., Liu, W., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38904 · Cited by 146
Epigenetics of idiopathic pulmonary fibrosis
Yang, I. V., & Schwartz, D. A. (2014) · Translational research · doi:10.1016/j.trsl.2014.03.011 · Cited by 144
Hamai, K., Iwamoto, H., Ishikawa, N., Horimasu, Y., Masuda, T., Miyamoto, S., Nakashima, T., Ohshimo, S., Fujitaka, K., Hamada, H., et al. (2016) · Disease Markers · doi:10.1155/2016/4759040 · Cited by 140
Bauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., & Nayler, O. (2017) · ERJ Open Research · doi:10.1183/23120541.00074-2016 · Cited by 139
Blood Biomarkers MMP-7 and SP-A
Song, J. W., Do, K., Jang, S. J., Colby, T. V., Han, S., & Kim, D. S. (2013) · CHEST Journal · doi:10.1378/chest.11-2735 · Cited by 137
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
van der Velden, J. L. J., Ye, Y., Nolin, J. D., Hoffman, S. M., Chapman, D. G., Lahue, K. G., Abdalla, S. T., Chen, P., Liu, Y., Bennett, B. L., et al. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0117-2 · Cited by 133
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Biomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132
Validation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis
Tzouvelekis, A., Herazo‐Maya, J. D., Slade, M., Chu, J., Deiuliis, G., Ryu, C., Li, Q., Sakamoto, K., Ibarra, G., Pan, H., et al. (2017) · Respirology · doi:10.1111/resp.12920 · Cited by 130
Self-citationGenetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment
Kaur, A., Mathai, S. K., & Schwartz, D. A. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00154 · Cited by 132
Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis
Donahoe, M., Valentine, V. G., Chien, N., Gibson, K. F., Raval, J. S., Saul, M., Xue, J., Zhang, Y., & Duncan, S. R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127771 · Cited by 125
Self-citationFan, M.-H., Zhu, Q., Li, H., Ra, H.-J., Majumdar, S., Gulick, D. L., Jerome, J. A., Madsen, D. H., Christofidou‐Solomidou, M., Speicher, D. W., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.701433 · Cited by 126
Normativa sobre el diagnóstico y tratamiento de la fibrosis pulmonar idiopática
Xaubet, A., Ancochea, J., Bollo, E., Fernández‐Fabrellas, E., Franquet, T., Molina‐Molina, M., Montero, M. A., & Serrano‐Mollar, A. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.03.011 · Cited by 123
Yang, G., Yang, L., Wang, W., Wang, J., Wang, J., & Xu, Z. (2015) · Gene · doi:10.1016/j.gene.2015.02.065 · Cited by 119
Peripheral blood biomarkers in idiopathic pulmonary fibrosis
Vij, R., & Noth, I. (2012) · Translational research · doi:10.1016/j.trsl.2012.01.012 · Cited by 117
Matrix Metalloproteinase-19 Is a Key Regulator of Lung Fibrosis in Mice and Humans
Yu, G., Kovkarova-Naumovski, E., Jara, P., Parwani, A. V., Kass, D. J., Ruiz, V., López-Otı́n, C., Rosas, I. O., Gibson, K. F., Cabrera, S., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0302oc · Cited by 115
Self-citationPrognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Khor, Y. H., Ng, Y., Barnes, H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0158-2019 · Cited by 119
Idiopathic Pulmonary Fibrosis: From Epithelial Injury to Biomarkers - Insights from the Bench Side
Kolb, Borensztajn, K., Crestani, B., & Kolb, M. R. J. (2013) · Respiration · doi:10.1159/000357598 · Cited by 114
Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes
Withana, N. P., Ma, X., McGuire, H. M., Verdoes, M., van der Linden, W. A., Ofori, L. O., Zhang, R., Li, H., Sanman, L. E., Wei, K., et al. (2016) · Scientific Reports · doi:10.1038/srep19755 · Cited by 114
Biomarkers in idiopathic pulmonary fibrosis
Zhang, Y., & Kaminski, N. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328356d03c · Cited by 113
Self-citationon behalf of the IPF-PRO Registry investigators, Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1103-4 · Cited by 105
MUC5B and Idiopathic Pulmonary Fibrosis
Yang, I. V., Fingerlin, T. E., Evans, C. M., Schwarz, M. I., & Schwartz, D. A. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201503-110aw · Cited by 103
van den Blink, B., Dillingh, M. R., Ginns, L. C., Morrison, L. D., Moerland, M., Wijsenbeek, M. S., Trehu, E., Bartholmai, B. J., & Burggraaf, J. (2016) · European Respiratory Journal · doi:10.1183/13993003.00850-2015 · Cited by 98
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Goldberg, H. J., Collard, H. R., El‐Chemaly, S., Flaherty, K. R., Hunninghake, G. M., Lasky, J. A., Lederer, D. J., Machado, R. F., Martínez, F. J., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.09.052 · Cited by 100
Raghu, G., Richeldi, L., Jagerschmidt, A., Martin, V., Subramaniam, A., Ozoux, M., Espéret, C., & Soubrane, C. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1083 · Cited by 96
Raghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. M., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2213so · Cited by 108
Association between telomere length and survival in patients with idiopathic pulmonary fibrosis
Dai, J., Cai, H., Li, H., Zhuang, Y., Min, H., Wen, Y., Yang, J., Gao, Q., Shi, Y. P., & Yi, L. (2015) · Respirology · doi:10.1111/resp.12566 · Cited by 96
Evaluating disease severity in idiopathic pulmonary fibrosis
Robbie, H., Daccord, C., Chua, F., & Devaraj, A. (2017) · European Respiratory Review · doi:10.1183/16000617.0051-2017 · Cited by 93
Yang, I. V., Luna, L. G., Cotter, J., Talbert, J. L., Leach, S. M., Kidd, R., Turner, J., Kummer, N., Kervitsky, D. J., Brown, K. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037708 · Cited by 94
Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis
Gille, T., Didier, M., Boubaya, M., Moya, L., Sutton, A., Carton, Z., Baran‐Marszak, F., Sadoun-Danino, D., Israël‐Biet, D., Cottin, V., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01934-2016 · Cited by 98
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development
Samarelli, A. V., Masciale, V., Aramini, B., Coló, G. P., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212179 · Cited by 94
Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis
Kropski, J. A., Young, L. R., Cogan, J. D., Mitchell, D. B., LANCASTER, L. H., Worrell, J. A., Markin, C. R., Liu, N., Mason, W. R., Fingerlin, T. E., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1820pp · Cited by 96
Biomarker signatures for progressive idiopathic pulmonary fibrosis
Clynick, B., Corte, T. J., Jo, H. E., Stewart, I., Glaspole, I. N., Grainge, C., Maher, T. M., Navaratnam, V., Hubbard, R., Hopkins, P. M. A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01181-2021 · Cited by 86
Doyle, T. J., Lee, J. S., Dellaripa, P. F., Lederer, J. A., Matteson, E. L., Fischer, A., Ascherman, D. P., Glassberg, M. K., Ryu, J. H., Danoff, S. K., et al. (2014) · CHEST Journal · doi:10.1378/chest.13-2408 · Cited by 88
Staging of idiopathic pulmonary fibrosis: past, present and future
Kolb, M. R. J., & Collard, H. R. (2014) · European Respiratory Review · doi:10.1183/09059180.00002114 · Cited by 89
Recent advances in understanding idiopathic pulmonary fibrosis
Daccord, C., & Maher, T. M. (2016) · F1000Research · doi:10.12688/f1000research.8209.1 · Cited by 91
IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity
Yang, L., Herrera, J., Gilbertsen, A. J., Hong, X., Smith, K. A., Benyumov, A. O., Bitterman, P. B., & Henke, C. A. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00200.2017 · Cited by 87
S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose
Behr, J., Günther, A., Ammenwerth, W., Bittmann, I., Bonnet, R. B., Buhl, R., Eickelberg, O., Ewert, R., Gläser, S., Gottlieb, J., et al. (2013) · Pneumologie · doi:10.1055/s-0032-1326009 · Cited by 90
The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and Mortality
Sanders, J. L., Putman, R. K., Dupuis, J., Xu, H., Murabito, J. M., Araki, T., Nishino, M., Benjamin, E. J., Levy, D., Ramachandran, V. S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202007-2993oc · Cited by 84
Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a Review
Zaman, T., & Lee, J. S. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0210-7 · Cited by 91
Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis
Yan, Z., Zhang, K., & Zhu, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.028 · Cited by 83
Adegunsoye, A., Alqalyoobi, S., Linderholm, A., Bowman, W. S., Lee, C. T., Pugashetti, J. V., Sarma, N., Ma, S.-F., Haczku, A., Sperling, A., et al. (2020) · Chest · doi:10.1016/j.chest.2020.04.066 · Cited by 82
Morais, A., Beltrão, M., Sokhatska, O., Costa, D., Melo, N., Mota, P. C., Marques, A., & Delgado, L. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.06.003 · Cited by 78
Bowman, W. S., Echt, G., & Oldham, J. M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.680997 · Cited by 81
Paulín, F., Doyle, T. J., Fletcher, E. A., Ascherman, D. P., & Rosas, I. O. (2015) · Revista de investigaci�n Cl�nica · doi:10.1016/s0034-8376(25)00249-9 · Cited by 77
Lindell, K. O., Kavalieratos, D., Gibson, K. F., Moreines, L. T., & Rosenzweig, M. Q. (2016) · Heart & Lung · doi:10.1016/j.hrtlng.2016.10.002 · Cited by 76
Self-citationRegulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis
Moore, M. W., & Herzog, E. L. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0017-8 · Cited by 80
Rieder, F., de Bruyn, J. R., Pham, B. T., Katsanos, K. H., Annese, V., Higgins, P., Magro, F., & Dotan, I. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.03.009 · Cited by 79
VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis
Agassandian, M., Tedrow, J. R., Sembrat, J., Kass, D. J., Zhang, Y., Goncharova, E. A., Kaminski, N., Mallampalli, R. K., & Vuga, L. J. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.09.003 · Cited by 75
Self-citationSequential changes of serum KL-6 predict the progression of interstitial lung disease
Jiang, Y., Luo, Q., Han, Q., Huang, J., Ou, Y., Chen, M., Wen, Y., Mosha, S. S., Deng, K., & Chen, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.76 · Cited by 74
Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis
Oldham, J. M., Huang, Y., Bose, S., Ma, S.-F., Kim, J. S., Schwab, A., Ting, C., Mou, K., Lee, C. T., Adegunsoye, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0117oc · Cited by 72
Jee, A. S., Sahhar, J., Youssef, P. P., Bleasel, J. F., Adelstein, S., Nguyen, M., & Corte, T. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.014 · Cited by 76
IPF clinical trial design and endpoints
Nathan, S. D., & Meyer, K. C. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000091 · Cited by 71
The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis
Ohta, S., Okamoto, M., Fujimoto, K., Sakamoto, N., Takahashi, K., Yamamoto, H., Kushima, H., Ishii, H., Akasaka, K., Ono, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174547 · Cited by 74
Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night
Schiza, S. E., Mermigkis, C. M., Margaritopoulos, G. A., Daniil, Z. D., Harari, S. A., Poletti, V. E., Renzoni, E. A., Torre, O., Visca, D., Bouloukaki, I., et al. (2015) · European Respiratory Review · doi:10.1183/16000617.00009114 · Cited by 74
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martínez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 69
Self-citationLee, S. H., Kim, S. Y., Kim, D. S., Kim, Y. W., Chung, M. P., Uh, S. T., Park, C., Jeong, S. H., Park, Y. B., Lee, H. L., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0454-0 · Cited by 68
Karampitsakos, Τ., Torrisi, S. E., Antoniou, K. M., Manali, E. D., Korbila, I. P., Παπαϊωάννου, Ο., Sampsonas, F., Katsaras, M., Vasarmidi, E., Papakosta, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01725-9 · Cited by 71
Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib
Bellamri, N., Morzadec, C., Joannes, A., Lecureur, V., Wollin, L., Jouneau, S., & Vernhet, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.061 · Cited by 72
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Wilkes, D. S., Chew, T., Flaherty, K. R., Frye, S. B., Gibson, K. F., Kaminski, N., Klemsz, M. J., Lange, W., Noth, I., & Rothhaar, K. (2015) · European Respiratory Journal · doi:10.1183/09031936.00105314 · Cited by 67
Self-citation
Metadata
- Authors
- Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L. J., Lindell, K. O., Klesen, M., Zhang, Y., & Gibson, K. F.
- Affiliations
- University of Pittsburgh (US)
- Centocor R&D Inc., Radnor, Pennsylvania
- Corresponding author
- Gibson, Kevin F.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-01-01
- Volume
- 185
- Issue
- 1
- Pages
- 67-76
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC3262037
- OpenAlex
- W2007414618
- Cited by
- 381
- References
- 67
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 18 · 2023: 26 · 2022: 20 · 2021: 23 · 2020: 27 · 2019: 22 · 2018: 31 · 2017: 30 · 2016: 27 · 2015: 40 · 2014: 30 · 2013: 35 · 2012: 28
- FWCI
- 25.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P50 HL0894932, R01HL095397)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, plasma biomarkers, mortality prediction, MMP-7, ICAM-1, interleukin-8, VCAM-1, S100A12, surfactant protein D, transplant-free survival, progression-free survival, risk scoring, disease progression
- MeSH terms
- S100A12 Protein, Aged, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, S100 Proteins, Predictive Value of Tests, Cohort Studies, Biomarkers, Cell Adhesion Molecules, Proportional Hazards Models, Survival Analysis, Interleukin-8, Intercellular Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, Matrix Metalloproteinase 1, Matrix Metalloproteinases, Matrix Metalloproteinase 7, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
